Funding the Future of UK Life Sciences

From pre-clinical research to commercial manufacturing, we provide the specialist capital you need to accelerate discovery, pass milestones, and bring life-changing innovations to market.

Contact Us

We Understand the Biotechnology Journey.

Traditional lenders see risk in long R&D cycles and pre-profit balance sheets. We see potential. We understand that for an R&D Director or CSO, access to the right equipment isn't just a purchase—it's the critical enabler of your next breakthrough.

The CapEx Hurdle

High-value sequencers, analysers, and bioreactors strain your capital budget, delaying critical research.

The "Valley of Death"

You've secured grant or seed funding, but need commercial finance to bridge the gap to the next value inflection point.

The Equity Dilemma

Founders and investors want to preserve equity to fund core science, not to buy depreciating assets.

Solutions Built for the Lab and Beyond

Finance that aligns with your scientific and commercial milestones.

Lab Equipment Leasing

Access state-of-the-art technology without the burden of ownership. Our Operating Leases turn a large capital outlay into a simple, predictable operating expense, preserving cash for R&D and hiring.

R&D Tax Credit Loans

Your most valuable non-dilutive asset is your future HMRC refund. We provide loans against your claim, giving you the cash to reinvest in innovation today.

Manufacturing Asset Finance

As you scale towards commercial production, use Hire Purchase to acquire essential manufacturing, filling, and packaging lines, building equity with every payment.

Sale & Leaseback

Unlock a significant cash injection by selling us the equipment you already own. We lease it back to you without any operational disruption.

"Apex understood our needs immediately. They financed a full suite of analytical equipment which allowed us to complete our pre-clinical data package six months ahead of schedule. They are more than a lender; they are a strategic partner to the UK biotechnology community."

CFO, Oxford Biotechnology Company